Health TrialsbyHealthPanel

Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms

ConditionGastroenteritis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorCentral Hospital, Nancy, France

About this trial

Define the prevalence of fecal phage carriage in individuals with digestive symptoms (i) Determine the concentrations of infectious fecal phages in the stools of individuals with digestive symptoms (detection by culture)

(ii) Determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection)

(iii) Explore factors that could impact fecal phage carriage (patients with digestive symptoms vs. healthy individuals, immunocompromised patients vs. immunocompetent patients)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 60.

Persons having developed gastrointestinal symptoms justifying microbiological stool testing at the time of hospitalization.

Person having received full information on the organization of the research and not having objected to the use of this data

Disqualifiers

Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code.

Pregnant or breast-feeding women,

Minors (not emancipated),

Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice),

Trial population

patients hospitalized at the CHRU de Nancy with digestive symptoms requiring microbiological stool analysis

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • bacteriophage detection

    Other intervention

    bacteriophage detection

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: immunocompetent1 intervention
Group B: immunocompromised1 intervention

Trial outcomes

Primary outcomes

1

prevalence of faecal phage carriage

define the prevalence of faecal phage (coliphage) carriage in individuals presenting with digestive symptoms.

Time frame
baseline

Secondary outcomes

1

concentrations of infectious fecal phages

Determine the concentrations of infectious fecal phages in the stools of individuals with digestive symptoms (detection by culture)

Time frame
baseline
2

fecal phage genome concentrations

determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection)

Time frame
baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Central Hospital, Nancy, France

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: